Wockhardt Ltd's shares hit a 10% upper circuit on Friday after the company announced positive results for its new drug, Zaynich. The drug achieved a 96.8% clinical cure rate in a Phase III trial for complicated Urinary Tract Infection (cUTI), boosting investor confidence in the company's growth potential in the pharmaceutical sector.